Giacomo Ceoldo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giacomo Ceoldo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Danilo Pellin
Division of Hematology/Oncology, Boston Children’s Hospital, Boston, USA
2 shared publications Thao Thi Dang
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA, Indianapolis, Indiana, United States
2 shared publications- Tsai-Yu Lin
Indiana University School of Medicine, Indianapolis, IN, USA, Indianapolis, Indiana, United States
2 shared publications Ami J. Shah
Division of Pediatric Hematology/ Oncology/ Stem cell transplantation and Regenerative Medicine, Stanford school of medicine, Palo Alto, CA, United States
1 shared publicationAugustine Fernandes
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA, United States
1 shared publicationBeatriz Campo Fernandez
Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, Los Angeles, California, United States
1 shared publication
Latest Publications
- Open Access
- 20 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 4991-5002
Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease
Sickle cell disease (SCD) is a monogenic disorder where autologous gene therapy may offer a safer curative alternative to allogeneic transplantation. We report outcomes from a Phase I/II study using the Lenti/G-βAS3-FB lentiviral vector, encoding an anti-sickling β-globin. This trial was registered at ClinicalTrials.gov (NCT02247843). This single-site study treated four adults with severe SCD. The first patient was treated using the original Lenti/βAS3-FB and initial protocol, which resulted in suboptimal clinical response. Subsequent protocol refinements included improved hematopoietic stem and progenitor cell (HSPC) collection using plerixafor-mobilized peripheral blood apheresis with pre-collection erythrocytapheresis, and use of an optimized lentiviral vector with a transduction enhancer. All patients received myeloablative busulfan conditioning followed by infusion of gene-modified autologous HSPCs. Primary endpoints were safety and feasibility; secondary endpoints included gene marking, therapeutic hemoglobin expression, and clinical outcomes. All patients achieved hematopoietic recovery without rescue transplantation. The first patient demonstrated low gene marking (peak vector copy number [VCN] 0.035) and undetectable HbAS3 expression, with minimal clinical benefit. In contrast, the three patients treated with the optimized protocol achieved higher and sustained gene marking (peak granulocyte VCNs ~0.5-2.0) and persistent HbAS3 expression. These patients experienced some reductions in vaso-occlusive crises and transfusion requirements, with two becoming transfusion-independent. No insertional oncogenesis was observed. This trial highlights the necessity of optimized vector design and transduction protocols to achieve durable gene expression. While this specific vector will not be pursued further, the study provides crucial insights into gene therapy protocol development.
- 20 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 4991-5002
Open AccessClinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease
Sickle cell disease (SCD) is a monogenic disorder where autologous gene therapy may offer a safer curative alternative to allogeneic transplantation. We report outcomes from a Phase I/II study using the Lenti/G-βAS3-FB lentiviral vector, encoding an anti-sickling β-globin. This trial was registered at ClinicalTrials.gov (NCT02247843). This single-site study treated four adults with severe SCD. The first patient was treated using the original Lenti/βAS3-FB and initial protocol, which resulted in suboptimal clinical response. Subsequent protocol refinements included improved hematopoietic stem and progenitor cell (HSPC) collection using plerixafor-mobilized peripheral blood apheresis with pre-collection erythrocytapheresis, and use of an optimized lentiviral vector with a transduction enhancer. All patients received myeloablative busulfan conditioning followed by infusion of gene-modified autologous HSPCs. Primary endpoints were safety and feasibility; secondary endpoints included gene marking, therapeutic hemoglobin expression, and clinical outcomes. All patients achieved hematopoietic recovery without rescue transplantation. The first patient demonstrated low gene marking (peak vector copy number [VCN] 0.035) and undetectable HbAS3 expression, with minimal clinical benefit. In contrast, the three patients treated with the optimized protocol achieved higher and sustained gene marking (peak granulocyte VCNs ~0.5-2.0) and persistent HbAS3 expression. These patients experienced some reductions in vaso-occlusive crises and transfusion requirements, with two becoming transfusion-independent. No insertional oncogenesis was observed. This trial highlights the necessity of optimized vector design and transduction protocols to achieve durable gene expression. While this specific vector will not be pursued further, the study provides crucial insights into gene therapy protocol development.
- Open Access
- 23 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Modeling integration site data for safety assessment with MELISSA
Gene and cell therapies pose safety concerns due to potential insertional mutagenesis by viral vectors. We introduce MELISSA, a regression-based statistical framework for analyzing Integration Site (IS) data to assess insertional mutagenesis risk, by estimating and comparing gene-specific integration rates and their impact on clone fitness. We characterized the IS profile of a lentiviral vector on Mesenchymal Stem Cells (MSCs) and compared it with that of Hematopoietic Stem and Progenitor Cells (HSPCs). We applied MELISSA to published IS data from patients enrolled in gene therapy clinical trials, successfully identifying both known and novel genes that drive changes in clone growth through vector integration. MELISSA offers a quantitative tool to bridge the gap between IS data and safety and efficacy evaluation, facilitating the generation of comprehensive data packages supporting Investigational New Drug (IND) and Biologics License (BLA) applications and the development of safe and effective gene and cell therapies.
- 23 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessModeling integration site data for safety assessment with MELISSA
Gene and cell therapies pose safety concerns due to potential insertional mutagenesis by viral vectors. We introduce MELISSA, a regression-based statistical framework for analyzing Integration Site (IS) data to assess insertional mutagenesis risk, by estimating and comparing gene-specific integration rates and their impact on clone fitness. We characterized the IS profile of a lentiviral vector on Mesenchymal Stem Cells (MSCs) and compared it with that of Hematopoietic Stem and Progenitor Cells (HSPCs). We applied MELISSA to published IS data from patients enrolled in gene therapy clinical trials, successfully identifying both known and novel genes that drive changes in clone growth through vector integration. MELISSA offers a quantitative tool to bridge the gap between IS data and safety and efficacy evaluation, facilitating the generation of comprehensive data packages supporting Investigational New Drug (IND) and Biologics License (BLA) applications and the development of safe and effective gene and cell therapies.
- 24 January 2024
- Published by Elsevier in Social Networks
- Vol. 78, 150-163
Stochastic actor oriented model with random effects
- 24 January 2024
- Published by Elsevier in Social Networks
- Vol. 78, 150-163
Stochastic actor oriented model with random effects